Bayer Pharma Aktiengesellschaft

Leadd B.v.

Schering Aktiengesellschaft

Luisella Toschi

Udo Albus

Thomas Ernst Müller

Klemens Lustig

Michael Hahn

Heinrich Meier

Martina Delbeck

Bertram Weiss

Doris Gehring

Jennifer Leigh Rohn

Björn Rosenstein

Astrid Adriana A M Danen-van Oorschot

Mathieu Hubertus M Noteborn

Johanna Mosig

Werner Skuballa

William J Guilford

Bernd Buchmann

Bernhard Lindenthal

Daryl Faulds

Gernot Langer

Thomas Müller

Judy Li

Thomas Muller

Bjorn Rosenstein

The present application relates to novel 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives, to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases, and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for treatment and/or prevention of respiratory disorders including, sleep-related respiratory disorders such as obstructive sleep apnoeas and central sleep apnoeas and snoring.

2-phenyl-3-(piperazinomethyl)imidazo[1,2-A]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders

The present application relates to novel (2-phenylimidazo[1,2-a]pyridin-3-yl)methyl-substituted perhydropyrrolo[3,4-c]pyrrole derivatives, to methods for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of respiratory disorders including sleep-related respiratory disorders such as obstructive sleep apneas and central sleep apneas and snoring.

Substituted perhydropyrrolo[3,4-c]pyrrole derivatives and the use of same

The invention relates to the field of apoptosis. The invention provides novel therapies, for example, novel combinatorial therapies or novel therapeutic compounds that can work alone, sequentially to, or jointly with Apoptin, especially in those cases wherein p53 is completely or partially non-functional.

Apoptin-associating protein

The present invention relates to 9-chloroprostaglandin derivatives of the general formula I which may be advantageous for the treatment of fertility problems. 

9-chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments

The invention relates to the field of apoptosis. The invention provides novel therapeutic possibilities, for example novel combinatorial therapies or novel therapeutic compounds that can work alone, sequentially to, or jointly with Apoptin, especially in those cases wherein p53 is (partly) nonfunctional.

Growing community of inventors

Berlin, Germany

Luisella Toschi